[Editor's note: This story is reprinted from PharmAsia News - Nov. 30, 2009. Not a subscriber? To register for a free trial, click here. Look for part two of this interview in the Dec. 1 issue of PharmAsia News.]
He reassured the conference and India - with its well-established generics operations - that the U.S. biotech industry will welcome the entry of biosimilars into the U.S. market, though he expects there to be less competition than the traditional generics market because the regulatory barriers will be much higher for biosimilars than other generic drugs (PharmAsia News, Nov. 10, 2009).
Similarly, Western firms are looking to enhance their vaccine portfolios, and they are increasingly turning to
Greenwood spoke with PharmAsia News on his return from India about partnering prospects, regulatory concerns and potential roadblocks for
PharmAsia News: You met with the Indian Secretary for Pharmaceuticals and with the Minster of Science and Technology. What did you discuss with them?
Jim Greenwood: We were really focused on our upcoming partnering event. That was really the primary purpose of the visit was to promote this upcoming event in September in
We wanted the Indian government to be aware of the fact that we were doing this. We wanted them to know that we were partnering with ABLE, which is one of the corresponding biotech associations in
PharmAsia News: You also met with the Organization of Pharmaceutical Producers of
PharmAsia News: Does BIO intend to increase its lobbying efforts in
When we do these partnering events, and of course we do them in the
By bringing together this international biotech community, you tend to attract the policymakers that either want to be there to learn about the industry and partnering opportunities or to be seen themselves politically, to do some networking themselves. And that gives us an opportunity for us to expose them to some of the issue controversies that the industry faces, and gives us the opportunity to try to enlist their support and maximize the policy environment in a place like
PharmAsia News: What are some of the specific issues that you're concerned about in
They don't allow the patenting of certain kinds of entities that we do, and we think that should be with the international standard. I made that clear in my remarks at the convention where I spoke in Mumbai. [Editor's note: BIO later clarified that
PharmAsia News: Are you satisfied with their progress?
When we speak on this issue, we speak with our Indian counterparts with one voice. There's not a difference of opinion between
PharmAsia News: How would you characterize
- Daniel Poppy (email@example.com)